Benzinga Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably. Importance Rank: 1 read more